

Strengthening the reporting of Genetic Risk Prediction Studies: The GRIPS statement

A. Cecile J. W. Janssens, PhD¹, John P. A. Ioannidis, MD, DSc^{2,3,4,5,6}, Cornelia M. van Duijn, PhD¹, Julian Little, PhD⁷, and Muin J. Khoury, MD, PhD⁸; for the GRIPS Group

SUMMARY POINTS

- The rapid and continuing progress in gene discovery for complex diseases is fueling interest in the potential application of genetic risk models for clinical and public health practice.
- The number of studies assessing the predictive ability is steadily increasing, but the quality and completeness of reporting varies.
- A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic Risk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines.
- These recommendations aim to enhance the transparency of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct, or analysis.
- A detailed Explanation and Elaboration document is published as Supplemental Digital Content 1, <http://links.lww.com/GIM/A165>.

INTRODUCTION

The recent successes of genome-wide association studies and the promises of whole genome sequencing fuel interest in the translation of this new wave of basic genetic knowledge to health care practice. Knowledge about genetic risk factors may be used to target diagnostic, preventive, and therapeutic interventions for complex disorders based on a person's genetic risk, or to complement existing risk models based on classical non-genetic factors such as the Framingham risk score for cardiovascular disease. Implementation of genetic risk prediction in

health care requires a series of studies that encompass all phases of translational research,^{1,2} starting with a comprehensive evaluation of genetic risk prediction.

With increasing numbers of discovered genetic markers that can be used in future genetic risk prediction studies, it is crucial to enhance the quality of the reporting of these studies, since valid interpretation could be compromised by the lack of reporting of key information. Information that is often missing includes details in the description of how the study was designed and conducted (e.g., how genetic variants were selected and coded, how risk models or genetic risk scores were constructed, and how risk categories were chosen), or how the results should be interpreted. An appropriate assessment of the study's strengths and weaknesses is not possible without this information. There is ample evidence that prediction research often suffers from poor design and bias, and these may also have an impact on the results of the studies and on models of disease outcomes based on these studies.³⁻⁵ Although most prognostic studies published to date claim significant results,^{6,7} very few translate to clinically useful applications. Just as for observational epidemiological studies,⁸ poor reporting complicates the use of the specific study for research, clinical, or public health purposes and hampers the synthesis of evidence across studies.

Reporting guidelines have been published for various research designs,⁹ and these contain many items that are also relevant to genetic risk prediction studies. In particular, the guidelines for genetic association studies (STrengthening the REporting of Genetic Association studies [STREGA]) have relevant items on the assessment of genetic variants, and the guidelines for observational studies (Strengthening the Reporting of OBServational studies in Epidemiology [STROBE]) have relevant items about the reporting of study design. The guidelines for diagnostic studies (STAndards for Reporting Diagnostic accuracy [STARD]) and those for tumor marker prognostic studies (Guidelines for Reporting of tumor MARKer studies [REMARK]) include relevant items about test evaluation; the REMARK guidelines also have relevant items about risk prediction.¹⁰⁻¹³ However, none of these guidelines are fully suited to genetic risk prediction studies, an emerging field of investigation with specific methodological issues that need to be addressed, such as the handling of large numbers of genetic variants (from 10s to 10,000s) and flexibility in handling such large numbers in analyses. We organized a two-day workshop with an international group of risk prediction researchers, epidemiologists, geneticists, methodologists, statisticians, and journal editors to develop recommendations for the reporting of Genetic Risk Prediction Studies (GRIPS).

¹Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands; ²Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece; ³Biomedical Research Institute, Foundation for Research and Technology, Ioannina, Greece; ⁴Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts; ⁵Center for Genetic Epidemiology and Modeling and Tufts CTSI, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts; ⁶Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California; ⁷Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada; ⁸Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia.

A. Cecile J. W. Janssens, PhD, Department of Epidemiology, Erasmus University Medical Center, PO Box 2040 (room Ee 21-87), 3000 CA, Rotterdam, The Netherlands. E-mail: a.janssens@erasmusmc.nl.

Disclosure: See Acknowledgments for funding information and the membership of the GRIPS Group.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.geneticsinmedicine.org).

Published online ahead of print April 15, 2011.

DOI: 10.1097/GIM.0b013e318212fa82

response, or treatment-related harms. Risk prediction models are statistical algorithms, which may be simple genetic risk scores (e.g., risk allele counts), may be based on regression analyses (e.g., weighted risk scores or predicted risks), or may be based on more complex analytic approaches such as support vector machine learning or classification trees. The risk models may be based on genetic variants only, or include both genetic and nongenetic risk factors.¹⁴

AIMS AND USE OF THE GRIPS STATEMENT

The 25 items of the GRIPS statement are intended to maximize the transparency, quality, and completeness of reporting on research methodology and findings in a particular study. It is important to emphasize that these recommendations are guidelines only for how to report research and do not prescribe how to perform genetic risk prediction studies. The guidelines do not support or oppose the choice of any particular study design or method, e.g., the guidelines recommend that the study population should be described, but do not specify which population is preferred in a particular study.

The intended audience for the reporting guidelines is broad and includes epidemiologists, geneticists, statisticians, clinician scientists, and laboratory-based investigators who undertake genetic risk prediction studies, as well as journal editors and reviewers who have to appraise the design, conduct and analysis of such studies. In addition, it includes “users” of such studies who wish to understand the basic premise, design, and limitations of genetic prediction studies in order to interpret the results for their potential application in health care. These guidelines are also intended to ensure that essential data from future genetic risk prediction studies are presented in standardized form, which will facilitate information synthesis as part of systematic reviews and meta-analyses.

Items presented in the checklist are relevant for a wide array of risk prediction studies, because GRIPS focuses on the main aspects of the design and analysis of risk prediction studies. GRIPS does not address randomized trials that may be performed to test risk models, nor does it specifically address decision analyses, cost-effectiveness analyses, assessment of health care needs, or assessment of barriers to health care implementation.¹⁵ Once the performance of a risk model has been established, these next steps toward implementation require further evaluation.^{10,16} For the reporting of these studies, which go beyond the assessment of genetic risk models as such, additional requirements apply. However, proper documentation of genetic predictive research according to GRIPS might facilitate the translation of research findings into clinical and public health practice.

DEVELOPMENT OF THE GRIPS STATEMENT

The GRIPS statement was developed by a multidisciplinary panel of 25 risk prediction researchers, epidemiologists, geneticists, methodologists, statisticians, and journal editors, seven of whom were also part of the STREGA initiative.¹¹ They attended a two-day meeting in Atlanta, Georgia (US) in December 2009 that was sponsored by the US Centers for Disease Control and Prevention on behalf of the Human Genome Epidemiology Network (HuGENet).¹⁷ Participants discussed a draft version of the guidelines that was prepared and distributed before the meeting. This draft version was developed on the basis of existing reporting guidelines, namely STREGA,¹¹ REMARK,¹³ and STARD.¹² These were selected out of all available guidelines (see <http://www.equator-network.org>) because of their focus on observational study designs and genetic factors (STREGA), prediction models (REMARK), and test evaluation

(REMARK and STARD). During the meeting, methodological issues pertinent to risk prediction studies were addressed in presentations. Workshop participants were asked to change, combine, or delete proposed items and add additional items if necessary. Participants had extensive post-meeting electronic correspondence. To harmonize our recommendations for genetic risk prediction studies with previous guidelines, we chose the same wording for the items wherever possible. Finally, we tried to create consistency with previous guidelines for the evaluation of risk prediction studies of cardiovascular diseases and cancer.^{2,18} The final version of the checklist is presented in Table 1.

THE GRIPS EXPLANATION AND ELABORATION ARTICLE

Accompanying this GRIPS statement, an Explanation and Elaboration document has been written (see Supplemental Digital Content 1, <http://links.lww.com/GIM/A165>), modeled after those developed for other reporting guidelines.^{19–22} The Explanation and Elaboration document illustrates each item with at least one published example that we consider transparent in reporting, explains the rationale for its inclusion in the checklist, and presents details of the items that need to be addressed to ensure transparent reporting. The Explanation and Elaboration document was produced after the meeting (Supplemental Digital Content 1, <http://links.lww.com/GIM/A165>). The document was prepared by a small subgroup and shared with all workshop participants for additional revisions and final approval.

CONCLUDING REMARKS AND FUTURE DIRECTIONS

High-quality reporting reveals the strengths and weaknesses of empirical studies, facilitates the interpretation of the scientific and health care relevance of the results—especially within the framework of systematic reviews and meta-analyses—and helps build a solid evidence base for moving genomic discoveries into applications in health care practice. The GRIPS guidelines were developed to improve the transparency, quality and completeness of the reporting of genetic risk prediction studies. As outlined in the introduction, GRIPS does not prescribe how studies should be designed, conducted, or analyzed, and therefore the guidelines should not be used to assess the quality of empirical studies.²³ The guidelines should be used only to check whether all essential items are adequately reported.

Finally, the methodology for designing and assessing genetic risk prediction models is still developing. For example, newer measures of reclassification were first introduced in 2007,²⁴ and several alternative reclassification measures have been proposed.²⁵ Which measures to apply and when to use measures of reclassification are still subject to ongoing evaluation and discussion.²⁶ Furthermore, alternative strategies for constructing risk models other than simple regression analyses are being explored, and these may add increased complexity to the reporting. In formulating the items of the GRIPS statement, these methodological advances were anticipated. It is for this reason that the GRIPS statement recommends how a study should be reported and not how a study should be conducted or analyzed. Therefore, methodological and analytical developments will not immediately impact the validity and relevance of the items, but the GRIPS statement will be updated when this is warranted by essential new developments in the construction and evaluation of genetic risk models.

Table 1 Reporting recommendations for evaluations of risk prediction models that include genetic variants

TITLE & ABSTRACT	
	1 (a) Identify the article as a study of risk prediction using genetic factors. (b) Use recommended keywords in the abstract: genetic or genomic, risk, prediction.
INTRODUCTION	
Background and rationale	2 Explain the scientific background and rationale for the prediction study.
Objectives	3 Specify the study objectives and state the specific model(s) that is/are investigated. State if the study concerns the development of the model(s), a validation effort, or both.
METHODS	
Study design and setting	4* Specify the key elements of the study design and describe the setting, locations, and relevant dates, including periods of recruitment, follow-up, and data collection.
Participants	5* Describe eligibility criteria for participants, and sources and methods of selection of participants.
Variables: Definition	6* Clearly define all participant characteristics, risk factors and outcomes. Clearly define genetic variants using a widely-used nomenclature system.
Variables: Assessment	7* (a) Describe sources of data and details of methods of assessment (measurement) for each variable. (b) Give a detailed description of genotyping and other laboratory methods.
Variables: Coding	8 (a) Describe how genetic variants were handled in the analyses. (b) Explain how other quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why.
Analysis: Risk model construction	9 Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables were initially examined or considered for inclusion in models. Include details of any variable selection procedures and other model-building issues. Specify the horizon of risk prediction (e.g., 5-year risk).
Analysis: Validation	10 Specify the procedure and data used for the validation of the risk model.
Analysis: Missing data	11 Specify how missing data were handled.
Analysis: Statistical methods	12 Specify all measures used for the evaluation of the risk model including, but not limited to, measures of model fit and predictive ability.
Analysis: Other	13 Describe all subgroups, interactions, and exploratory analyses that were examined.
RESULTS	
Participants	14* Report the numbers of individuals at each stage of the study. Give reasons for nonparticipation at each stage. Report the number of participants not genotyped, and reasons why they were not genotyped.
Descriptives: Population	15* Report demographic and clinical characteristics of the study population, including risk factors used in the risk modeling.
Descriptives: Model estimates	16 Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted estimates and their precision from the full risk model(s) for each variable.
Risk distributions	17* Report distributions of predicted risks and/or risk scores.
Assessment	18 Report measures of model fit and predictive ability, and any other performance measures, if pertinent.
Validation	19 Report any validation of the risk model(s).
Other analyses	20 Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent.
DISCUSSION	
Limitations	21 Discuss limitations and assumptions of the study, particularly those concerning study design, selection of participants, and measurements and analyses, and discuss their impact on the results of the study.
Interpretation	22 Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.
Generalizability	23 Discuss the generalizability and, if pertinent, the health care relevance of the study results.
OTHER	
Supplementary information	24 State whether databases for the analyzed data, risk models, and/or protocols are or will become publicly available and if so, how they can be accessed.
Funding	25 Give the source of funding and the role of the funders for the present study. State whether there are any conflicts of interest.

*Marked items should be reported for every population in the study.

ACKNOWLEDGMENTS

The members of the GRIPS group are: A. Cecile J. W. Janssens, John P. A. Ioannidis, Sara Bedrosian, Paolo Boffetta, Siobhan M. Dolan, Nicole Dowling, Isabel Fortier, Andrew N. Freedman, Jeremy M. Grimshaw, Jeffrey Gulcher, Marta Gwinn, Mark A. Hlatky, Holly Janes, Peter Kraft, Stephanie Melillo, Christopher J. O'Donnell, Michael J. Pencina, David Ransohoff, Sheri D. Schully, Daniela Seminara, Deborah M. Winn, Caroline F. Wright, Cornelia M. van Duijn, Julian Little, and Muin J. Khoury.

Copyright: © 2011 Janssens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Workshop was sponsored by the Centers for Disease Control and Prevention on behalf of the Human Genome Epidemiology Network (HuGENet). The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the Department of Health and Human Services. A. Cecile J.W. Janssens is financially supported by grants from the Erasmus University Medical Center Rotterdam, the Center for Medical Systems Biology in the framework of the Netherlands Genomics Initiative (NGI) and the VIDI grant of the Netherlands Organisation for Scientific Research (NWO). John P.A. Ioannidis: Tufts CTSI is supported by the National Institutes of Health/National Center for Research Resources (UL1 RR025752). Opinions in this paper are those of the authors and do not necessarily represent the official position or policies of the Tufts CTSI. Julian Little holds a Canada Research Chair in Human Genome Epidemiology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: John Ioannidis is a member of the PLoS Medicine Editorial Board.

Provenance: Not commissioned; externally peer reviewed. In order to encourage dissemination of the GRIPS Statement, this article will also be published by *Annals of Internal Medicine*, *BMJ*, *Circulation: Cardiovascular Genetics*, *European Journal of Clinical Investigation*, *European Journal of Epidemiology*, *European Journal of Human Genetics*, *Genetics in Medicine*, *Genome Medicine*, and *Journal of Clinical Epidemiology*.

REFERENCES

1. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? *Genet Med* 2007;9:665–674.
2. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. *Circulation* 2009;119:2408–2416.
3. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. *J Natl Cancer Inst* 2007;99:236–243.
4. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. *J Natl Cancer Inst* 2005;97:1043–1055.
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). *Nat Clin Pract Urol* 2005;2:416–422.
6. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. *Eur J Cancer* 2007;43: 2559–2579.
7. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. *JAMA* 2009;302:2345–2352.
8. von Elm E, Egger M. The scandal of poor epidemiological research. *BMJ* 2004;329:868–869.
9. Simeria I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. *Eur J Clin Invest* 2010;40:35–53.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007;4:e296.
11. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. *PLoS Med* 2009;6:e22.
12. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003;326:41–44.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. Reporting recommendations for tumor marker prognostic studies. *J Clin Oncol* 2005; 23:9067–9072.
14. Janssens ACJW, Van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. *Genome Med* 2009; 1:20.
15. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. *Am J Epidemiol* 2010;172:517–524.
16. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. *BMJ* 2009;338:b606.
17. Khoury MJ, Dorman JS. The Human Genome Epidemiology Network. *Am J Epidemiol* 1998;148:1–3.
18. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. *J Natl Cancer Inst* 2005;97:715–723.
19. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. *Ann Intern Med* 2001;134:663–694.
20. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. *Ann Intern Med* 2003;138:W1–W12.
21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotsche PC, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009;6:e1000100.
22. Vandembroucke JP, von Elm E, Altman DG, Gotsche PC, Mulrow CD, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007;4:e297.
23. Vandembroucke JP. STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK . . . and CONSORT: for whom does the guideline toll? *J Clin Epidemiol* 2009; 62:594–596.
24. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation* 2007;115:928–935.
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* 2008;27:157–172.
26. Janssens ACJW, Khoury MJ. Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference? *Circ: Cardiovasc Genet* 2010;3:3–5.